Evidence map›Paper›PMID 34445691›Full record

ReviewInternational journal of molecular sciences2021

GPCR Partners as Cancer Driver Genes: Association with PH-Signal Proteins in a Distinctive Signaling Network.

Jeetendra Kumar Nag, Hodaya Malka, Priyanga Appasamy, Shoshana Sedley, Rachel Bar-Shavit

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in International journal of molecular sciences, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.1field-weighted citation impact, top 56% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 4 citations in OpenAlex.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Jeetendra Kumar NagSharett Institute of Oncology, Hadassah-Hebrew University Medical Center, POB 12000, Jerusalem 91120, Israel.
Hodaya MalkaSharett Institute of Oncology, Hadassah-Hebrew University Medical Center, POB 12000, Jerusalem 91120, Israel.
Priyanga AppasamySharett Institute of Oncology, Hadassah-Hebrew University Medical Center, POB 12000, Jerusalem 91120, Israel.
Shoshana SedleySharett Institute of Oncology, Hadassah-Hebrew University Medical Center, POB 12000, Jerusalem 91120, Israel.
Rachel Bar-ShavitSharett Institute of Oncology, Hadassah-Hebrew University Medical Center, POB 12000, Jerusalem 91120, Israel.ORCID 0000-0003-1162-9974
Hadassah Medical Center · IL

Funding

Israel Science Foundation 1420/16
6 · The paper itself

Abstract

The essential role of G-protein coupled receptors (GPCRs) in tumor growth is recognized, yet a GPCR based drug in cancer is rare. Understanding the molecular path of a tumor driver gene may lead to the design and development of an effective drug. For example, in members of protease-activated receptor (PAR) family (e.g., PAR

Indexed as

Gene ExpressionGene Expression Regulation, NeoplasticHumansNeoplasmsNeovascularization, PathologicPleckstrin Homology DomainsProtein DomainsReceptor, PAR-1Receptor, PAR-2Receptors, G-Protein-CoupledReceptors, Proteinase-ActivatedSignal TransductionReceptor, PAR-1Receptor, PAR-2Receptors, G-Protein-CoupledReceptors, Proteinase-ActivatedangiogenesisG-protein coupled receptors (GPCRs)protease-activated receptors (PARs)

Identifiers

PMID34445691
PMCPMC8396503
OpenAlexW3193804248

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.